#Taiwan #Taipei #Formosa Pharmaceuticals #Clobetasol Propionate #Saval Corporation

Formosa Pharmaceuticals Partners with Saval Corporation

In a significant move aimed at enhancing post-operative care, Formosa Pharmaceuticals, based in Taiwan, has inked an exclusive licensing agreement with Laboratorios Saval, a well-established pharmaceutical company in Chile. This partnership will allow Saval to commercialize Clobetasol Propionate Ophthalmic Suspension (0.05%), a cutting-edge treatment designed to alleviate post-operative inflammation and pain after ocular surgeries.

Overview of the Agreement

The agreement, which is a major development for both companies, underscores Formosa’s ambition to expand its reach in the Latin American market. Under this exclusive deal, Saval will have the rights to market this innovative treatment throughout Central and South America. Formosa Pharmaceuticals, trading under the stock number 6838.TW, has been recognized for its commitment to advancing medical therapies, particularly in the fields of ophthalmology and oncology.

This ophthalmic suspension has received FDA approval as of March 2024 and made its market debut in the U.S. in September 2024. Clobetasol Propionate is a super-potent corticosteroid, derived from Formosa’s proprietary APNT® nanoparticle formulation platform. This platform enhances the drug's dissolution and bioavailability, promising a more effective treatment regimen.

Benefits of Clobetasol Propionate

The innovative formulation of Clobetasol Propionate allows for a dosing schedule of twice daily for 14 days, which is expected to improve patient compliance significantly. According to recent surveys involving 100 ophthalmic surgeons, approximately 80% of patients reported being pain-free just four days after surgery, with adverse event rates remaining below 2%. These impressive outcomes make Clobetasol Propionate an attractive option in the relatively untapped ophthalmic corticosteroid market in Latin America, valued at nearly USD $7.5 million.

Statements from Leadership

Erick Co, President and CEO of Formosa Pharmaceuticals, expressed enthusiasm about the collaboration, stating, "We are pleased that Saval has recognized APP13007 as a valuable addition to their core ophthalmology business. Their extensive network across Latin America ensures that patients recovering from ocular procedures will have access to this promising therapy."

Similarly, Nicolás Donoso, CEO of Laboratorios Saval, emphasized the importance of this treatment for their portfolio, noting, "At Saval, we are dedicated to offering high-quality and cost-effective healthcare solutions across therapeutic areas in Latin America. APP13007 will significantly enhance our ophthalmology offerings, providing both physicians and patients with a superior treatment option."

About Formosa Pharmaceuticals

Formosa Pharmaceuticals is at the forefront of clinical-stage biotechnology, focusing on novel therapies for ophthalmology and oncology. With an emphasis on innovative technologies like the APNT® platform, Formosa has developed formulations that allow for easier administration of difficult-to-deliver medications. More details about their pipeline and innovative approaches can be found at their official website, formosapharma.com.

About Saval Corporation

Founded in 1938 and based in Santiago, Chile, Laboratorios Saval has made its presence felt in 14 countries across Central and South America. The company has a longstanding tradition of delivering affordable, high-quality pharmaceutical products, making them a trusted name in healthcare. For more information about Saval’s offerings, visit savalcorp.com.

In conclusion, this agreement between Formosa Pharmaceuticals and Saval Corporation promises to revolutionize the treatment landscape for ophthalmic care in Latin America, ultimately improving patient outcomes and setting new standards in post-operative recovery.